## RATEN AND TRADEMARK OFFICE

In Re Application of: Pnina FISHMAN et al

Application No.: 10/763,190

Conf. No. 6424

Filed: January 26, 2004

For: METHOD FOR MONITORING THE EFFECTIVENESS OF AN AC

SEP 1 9 2005

Art Unit: 1645

Examiner: Z. Howard

Washington, D.C.

Atty.'s Docket: FISHMAN=9B

Date: September 19, 2005

OR

OR

THE COMMISSIONER OF PATENTS U.S. Patent and Trademark Office Randolph Building, Mail Stop Amendments 401 Dulany Street Alexandria, VA 22314

Sir:

Transmitted herewith is a [ ] Amendment [XX] <u>SUPPLEMENTAL RESPONSE</u>

in the above-identified application.

[XX] Small Entity Status: Applicant(s) claim small entity status. See 37 C.F.R. §1.27.

[XX] No additional fee is required.

] The fee has been calculated as shown below:

	(Col. 1)		(Col. 2)	(Col. 3)		
	CLAIMS REMAINING AFTER AMENDMENT		HIGHEST NO. PREVIOUSLY PAID FOR	PRESENT EXTRA EQUALS		
TOTAL	* 17	MINUS	** 31	0		
INDEP.	* 2	MINUS	*** 3	0		
FIRST PRI						

_	SMALL ENTITY							
·	RATE	ADDITIONAL FEE						
	x 25	\$						
	x 100	\$						
	+ 180	\$						
ADDITIO	NAL FEE TOTAL	\$						

OTHER THAN	OTHER THAN SMALL ENTITY						
RATE	ADDITIONAL FEE						
x 50	\$						
x 200	\$						
+ 360	\$						
TOTAL	\$						

- If the entry in Col. 1 is less than the entry in Col. 2, write "0" in Col. 3.
- If the "Highest Number Previously Paid for" IN THIS SPACE is less than 20, write "20" in this space.
- If the "Highest Number Previously Paid for" IN THIS SPACE is less than 3, write "3" in this space.

The "Highest Number Previously Paid For" (total or independent) is the highest number found from the equivalent box in Col. 1 of a prior amendment of the number of claims originally filed.

Conditional Petition for Extension of Time

If any extension of time for a response is required, applicant requests that this be considered a petition therefor.

by 37 CFR 1.17 is calculated as shown below:

[ ]	It is hereby petitioned for an extension of time in accordance with 37 CFR 1.136(a	a).	The	appropriate	fee	requ	uired by	
	Small Entity	Other Than Small Entity						
	Response Filed Within		Response Filed Within					
	[ ] First - \$ 60.00	ſ	]	First	-	\$	120.00	
	[ ] Second - \$ 225.00	[	]	Second	-	\$	450.00	
	[ ] Third - \$ 510.00	[	]	Third	-	\$1,	020.00	
	[ ] Fourth - \$ 795.00	{	]	Fourth	-	\$1,	590.00	
	Month After Time Period Set	Month After Time Period Set						
	[ ] Less fees (\$) already paid for month(s) extension of time on	_						
[ ]	Please charge my Deposit Account No. 02-4035 in the amount of \$							
[ ]	Credit Card Payment Form, PTO-2038, is attached, authorizing payment in the ar	mo	unt c	of \$				
[ ]	A check in the amount of \$ is attached (check no. ).							
[XX]	The Commissioner is hereby authorized and requested to charge any additional f	fee:	s whi	ch mav be	real	ired	in conn	

in connection with this application or credit any overpayment to Deposit Account No. 02-4035. This authorization and request is not limited to payment of all fees associated with this communication, including any Extension of Time fee, not covered by check or specific authorization, but is also intended to include all fees for the presentation of extra claims under 37 CFR §1.16 and all patent processing fees under 37 CFR §1.17 throughout the prosecution of the case. This blanket authorization does not include patent issue fees under 37 CFR §1.18.

BROWDY AND NEIMARK, P.L.L.C.

Attorneys for Applicant(s)

Roger L. Browdy Registration No. 25,618

Facsimile:

(202) 737-3528 Telephone: (202) 628-5197



## THE UNITED STATES PATENT AND TRADEMARK OFFICE

Atty. Docket: FISHMAN=9B

In re Application of:

Pnina FISHMAN et al

Appln. No.: 10/763,190

Filed: January 26, 2004

For: METHOD FOR MONITORING THE EFFECTIVENESS OF AN AGENT INTERACTING WITH THE A3 ADENOSINE RECEPTOR

Art Unit: 1645

Examiner: Z.C. Howard

Washington, D.C.

September 19, 2005

## SUPPLEMENTAL RESPONSE

Honorable Commissioner for Patents U.S. Patent and Trademark Office Randolph Building, Mail Stop Amendments 401 Dulany Street Alexandria, VA 22314

Sir:

The present communication is intended to supplement applicants' amendment of September 6, 2005. At page 17 of applicants' amendment of September 6, 2005, applicants stated that a copy of Fishman et al, "Targeting the A3 adenosine receptor for cancer therapy: Inhibition of prostate carcinoma cell growth by A3AR agonists," Anticancer Res 23:2077-2083 (2003) would be filed in a supplemental response. A copy of this document is attached hereto.

Furthermore, on page 18 of applicants' amendment of September 6, 2005, applicants stated that results of additional experiments in cancer (hepatoma) and inflammatory